Durable Medical Equipment, Orthotics, Medical Supplies and Repairs/Replacements
UnitedHealthcare Commercial and Individual Exchange Medical Policy
Proprietary Information of UnitedHealthcare. Copyright 2023 United HealthCare Services, Inc.
were limited by low- or very low-quality evidence, PAP therapy may be worth considering for individuals with heart failure to
improve their quality of life.
Pépin et al. (2018) investigated adherence rates in patients with sleep apnea based on the type of positive airway pressure
(PAP) device used and the switching of PAP modality over time. The study included 198,890 patients which were divided into
three distinct groups: CPAP only (started on CPAP and stayed on CPAP, n = 189,724); ASV only (started on ASV and stayed on
ASV, n = 8,957); and Switch (started on CPAP, switched to ASV, n = 209). Adherence was defined as device usage for ≥ 4 hours
per night on 70% of nights during a consecutive 30-day period anytime during the first 3 months of initial use. Average usage
per day was calculated by dividing the total number of hours used in the period by the number of days in the period, where the
period was defined as day one to day thirty, day sixty, or day ninety, or to the end date of the specific therapy. Results identified
in the Switch group showed AHI decreased significantly on ASV versus CPAP use. At 90 days, adherence rates were 73.8% and
73.2% in the CPAP only and ASV only groups. In the Switch group, CPAP adherence was 62.7%, improving to 76.6% after the
switch to ASV. Mean device usage at 90 days was 5.27, 5.31, and 5.73 h/d in the CPAP only, ASV only, and Switch groups,
respectively. The authors concluded treatment-emergent or persistent CSA during CPAP reduced therapy adherence, but
adherence improved after switching from CPAP to ASV. Limitations included lack of demographic data, lack of comorbidity
conditions, and lack of information on specific rationale from clinicians when switching patients from CPAP to ASV. Further
studies, including RCTs, are needed to assess the effect of ASV in patients with persistent or treatment-emergent CSA during
CPAP.
Arzt et al. (2013) performed a multicentre, randomized, open label, parallel group trial, to assess whether ASV improves
daytime cardiac function in patients with heart failure (HF), sleep disordered breathing (SDB) and quality of life (QoL) when
compared to stable optimal medical management alone. Inclusion criteria consisted of participants aged 18 to 80 years of age,
contained CHF (NYHA class II-III) an LVEF ≤ 40%, stable optimal medical therapy for at least four weeks and an AHI ≥ 20 events
per hour as assessed by polysomnography. Seventy-two patients were randomly assigned to either the control group (optimal
medical management for HF) or the ASV group (ASV therapy in addition to optimal medical management). For the ASV group,
the expiratory positive airway pressure of the ASV device was set to the determined night CPAP titration. The minimum and
maximum pressures were set and the default backup rate of the machine was used. The information was obtained and saved
onto a smart card located in the device. The primary outcome of the trial was the change in left ventricular ejection fraction
(LVEF) within 12 weeks of treatment. The ASV device was used daily for approximately 4.5 hours with a mean expiratory
positive airway pressure of 8.1 ±1.7 cmH
2
O and the maximum inspiratory positive airway pressure of 14.0 ±5.3 cmH
2
O;
automatic backup rate was used in all patients. The authors found the change in LVEF, was similar in both the ASV and control
groups showing a modest improvement. In a sub-analyses of patients with OSA (n = 36) and CSA (n = 32), the change in LVEF
was not significantly different between the ASV and the control group. For secondary outcomes, AHI and central AHI were
decreased in the ASV group compared to the control group. It was concluded the trial supported that ASV was an effective
treatment for both CSA and OSA patients. Limitations included small sample size, changes in diuretic treatment for patients
with worsening symptoms during the trial and the per-protocol (PP) analysis did not comply with the calculated sample size.
Dellweg et al. (2013) compared noninvasive positive pressure ventilation (NPPV) and anticyclic servo-ventilation (SV) in thirty
patients that developed complex sleep apnea syndrome (CompSAS) during CPAP treatment. Participants were randomized
into one of two groups: 1) standard NPPV ventilator, or 2) dynamic SV. After titration to the respective device, patients were told
to use their device nightly during sleep and could contact the sleep center for any problems, however patients were not actively
contacted by the facility during the treatment period of 6 weeks. Compliance was recorded from the machines. The authors
found NPPV and servo-ventilation were able to suppress central and obstructive events during initial titration, but after six weeks
SV was shown to be superior to NPPV. Limitations included small sample size, lack of blinding and occurrence of potential
manual titration from patient.
Chowdhuri et al. (2012) conducted a retrospective review over 3 years on the management of CSA associated with varying
comorbidities and opioid use for patients and report the effectiveness of titration with PAP (used alone or in conjunction with
oxygen). Three groups of patients were studied: CPAP only, CPAP+O
2
and BPAP+O
2
. The CSA treatment protocol consisted of
positive pressure titration initiated at CPAP 4-5 cm H
2
O and titrated upward to 10-14 cm H
2
O. If frequent central apneas
persisted at the designated CPAP pressures of 10-14 cm H
2
O, then no further increase of CPAP occurred, but instead oxygen
was introduced. If central apneas persisted despite the addition of supplemental O
2
, CPAP was switched to BPAP while
maintaining oxygen saturation ≥ 93%. There was an optimal response in 127 of the 151 patients following the protocol; in
addition, the most effective common therapeutic modality was CPAP which occurred in 48% of the patients. Reduction in AHI
and CAI was achieved in each group. In twelve patients, the addition of oxygen did not eliminate central apnea adequately (CAI